ECLIPSE – A randomized phase 3 trial for 177-Lu-PSMA-I&T in patients with mCRPC

Project specs


Eric Lensymer






A new therapy, 177-Lu-PSMA-I&T, is being investigated for patients with metastatic castration-resistant prostate cancer (mCRPC) within the ECLIPSE clinical trial. The investigational therapy targets PSMA (prostate-specific membrane antigen), a biomarker expressed in 95% of prostate cancer cells. Upon binding to the PSMA receptor, the medication is internalised within the cancer cell. The radioactive medication emits DNA-breaking radiation, leading to targeted cell death. It is hoped that the therapy will provide better treatment for patients with mCRPC when compared with standard-of-care hormone therapy.

Researcher Profile

Curium, the sponsor of the ECLIPSE Trial, is the largest manufacturer of nuclear medicine products in the world. With over 100 years of history in nuclear medicine, Curium, headquatered in Paris with North American Headquarters in St. Louis, employs over 2000 people globally, provides medicine to 60 countries with greater than 50 products serving 6000 hospitals worldwide impacting 14 million patients annually. Our name “Curium” honors the legacy of pioneering radioactive researchers Marie and Pierre Curie after whom the radioactive element curium was named. Curium’s vision is to redefine the experience of cancer through our trusted legacy in nuclear medicine.

How did UK domestic abuse specialists manage during the…

Domestic abuse spiked during the Covid-19 pandemic. Calls and website…